SGHT vs. KIDS, TMCI, SMLR, NNOX, CLPT, TCMD, DCTH, ZIMV, CVRX, and NPCE
Should you be buying Sight Sciences stock or one of its competitors? The main competitors of Sight Sciences include OrthoPediatrics (KIDS), Treace Medical Concepts (TMCI), Semler Scientific (SMLR), Nano-X Imaging (NNOX), ClearPoint Neuro (CLPT), Tactile Systems Technology (TCMD), Delcath Systems (DCTH), ZimVie (ZIMV), CVRx (CVRX), and NeuroPace (NPCE). These companies are all part of the "medical equipment" industry.
Sight Sciences vs.
OrthoPediatrics (NASDAQ:KIDS) and Sight Sciences (NASDAQ:SGHT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, community ranking, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.
In the previous week, Sight Sciences had 7 more articles in the media than OrthoPediatrics. MarketBeat recorded 13 mentions for Sight Sciences and 6 mentions for OrthoPediatrics. OrthoPediatrics' average media sentiment score of 0.52 beat Sight Sciences' score of 0.04 indicating that OrthoPediatrics is being referred to more favorably in the media.
OrthoPediatrics has higher revenue and earnings than Sight Sciences. OrthoPediatrics is trading at a lower price-to-earnings ratio than Sight Sciences, indicating that it is currently the more affordable of the two stocks.
OrthoPediatrics currently has a consensus price target of $39.00, indicating a potential upside of 43.59%. Sight Sciences has a consensus price target of $4.72, indicating a potential upside of 66.78%. Given Sight Sciences' higher possible upside, analysts clearly believe Sight Sciences is more favorable than OrthoPediatrics.
OrthoPediatrics has a net margin of -15.00% compared to Sight Sciences' net margin of -63.30%. OrthoPediatrics' return on equity of -5.78% beat Sight Sciences' return on equity.
69.1% of OrthoPediatrics shares are held by institutional investors. Comparatively, 55.5% of Sight Sciences shares are held by institutional investors. 31.8% of OrthoPediatrics shares are held by company insiders. Comparatively, 28.9% of Sight Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
OrthoPediatrics has a beta of 1.14, meaning that its share price is 14% more volatile than the S&P 500. Comparatively, Sight Sciences has a beta of 2.57, meaning that its share price is 157% more volatile than the S&P 500.
OrthoPediatrics received 294 more outperform votes than Sight Sciences when rated by MarketBeat users. Likewise, 64.26% of users gave OrthoPediatrics an outperform vote while only 28.81% of users gave Sight Sciences an outperform vote.
Summary
OrthoPediatrics beats Sight Sciences on 13 of the 18 factors compared between the two stocks.
Get Sight Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for SGHT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sight Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:SGHT) was last updated on 1/21/2025 by MarketBeat.com Staff
Free SGHT Stock Alerts